Phase II study of everolimus in metastatic urothelial cancer
Open Access
- 3 April 2013
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 112 (4), 462-470
- https://doi.org/10.1111/j.1464-410x.2012.11720.x
Abstract
What's known on the subject? and What does the study add? No recent advances have been made in the treatment of patients with advanced bladder cancer and, to date, targeted therapies have not resulted in an improvement in outcome. The mammalian target of rapamycin pathway has been shown to be up‐regulated in bladder cancer and represents a rational target for therapeutic intervention. In the present phase II study of everolimus, one near‐complete response, one partial response and several minor responses suggest that everolimus possesses biological activity in a subset of patients with bladder cancer. To maximize benefit from targeted agents such as everolimus, the preselection of patients based on molecular phenotype is required. Objective To assess the efficacy and tolerability of everolimus in advanced urothelial carcimoma (UC). Patients and Methods The present study comprised a single‐arm, non‐randomized study in which all patients received everolimus 10 mg orally once daily continuously (one cycle = 4 weeks). In total, 45 patients with metastatic UC progressing after one to four cytotoxic agents were enrolled between February 2009 and November 2010 at the Memorial Sloan‐Kettering Cancer Center. The primary endpoints were 2‐month progression‐free survival (PFS) and the safety of everolimus, with the secondary endpoint being the response rate. A Simon minimax two‐stage design tested the null hypothesis that the true two month PFS rate was ≤50%, as opposed to the alternative hypothesis of ≥70%. Results The most common grade 3/4 toxicities were fatigue, infection, anaemia, lymphopaenia, hyperglycaemia and hypophosphataemia. There were two partial responses in nodal metastases, with one patient achieving a 94% decrease in target lesions and remaining on drug at 26 months. An additional 12 patients exhibited minor tumour regression. There were 23 of 45 (51%) patients who were progression‐free at 2 months with a median (95% CI) PFS of 2.6 (1.8–3.5) months and a median (95% CI) overall survival of 8.3 (5.5–12.1) months. No clear association was observed between mammalian target of rapamycin pathway marker expression and 2‐month PFS. Conclusions Although everolimus did not meet its primary endpoint, one partial response, one near‐complete response and twelve minor regressions were observed. Everolimus possesses meaningful anti‐tumour activity in a subset of patients with advanced UC. Studies aiming to define the genetic basis of everolimus activity in individual responders are ongoing.Keywords
This publication has 30 references indexed in Scilit:
- Management of invasive bladder cancer in patients who are not candidates for or decline cystectomyTherapeutic Advances in Urology, 2011
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous SclerosisThe New England Journal of Medicine, 2010
- Hypoxia‐inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implicationsBJU International, 2010
- Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical OncologyJournal of Clinical Oncology, 2009
- Genetic Predictors of MEK Dependence in Non–Small Cell Lung CancerCancer Research, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignanciesMolecular Cancer Therapeutics, 2008
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient GlioblastomaPLoS Medicine, 2008
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989